Solomon Owusu, MD
Internal Medicine · Jersey City, NJNPI 1487723243
Payments from drug & device makers
Across 451 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$957
- Boehringer Ingelheim$687
- Novo Nordisk$463
- Johnson & Johnson$445
- Sanofi-aventis U.S. LLC$312
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,758100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $1,644 |
| GSK | 79 | $957 |
| Boehringer Ingelheim | 41 | $687 |
| Novo Nordisk | 32 | $463 |
| Johnson & Johnson | 50 | $445 |
| Sanofi-aventis U.S. LLC | 22 | $312 |
| Sunovion Pharmaceuticals Inc. | 20 | $292 |
| Bayer | 15 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $259 |
| Lilly USA, LLC | 16 | $245 |
| Merck | 14 | $190 |
| AbbVie(2 entities) | 9 | $130 |
| Novartis | 8 | $123 |
| Dexcom, Inc. | 5 | $96 |
| Amgen | 6 | $82 |
| Nabriva Therapeutics, PLC | 6 | $76 |
| Currax Pharmaceuticals LLC | 5 | $70 |
| Mannkind Corporation | 5 | $70 |
| Pfizer | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $47 |
| Scilex Pharmaceuticals Inc. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 1 | $28 |
| Exact Sciences | 1 | $25 |
| Amarin Pharma, Inc. | 2 | $24 |
| Althera Pharmaceuticals LLC | 2 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $18 |
| Intuity Medical Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Intra-sana Laboratories | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,788 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 152 | $103,499 |
| OzempicSemaglutide | 94 | $101,247 |
| RybelsusSemaglutide | 56 | $84,841 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $72,833 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $62,149 |
| FarxigaDapagliflozin Propanediol | 74 | $53,972 |
| JardianceEmpagliflozin | 59 | $53,092 |
| EliquisApixaban | 49 | $37,990 |
| EntrestoSacubitril/Valsartan | 50 | $36,009 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 47 | $29,651 |
| MounjaroTirzepatide | 25 | $26,762 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $22,606 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 36 | $22,034 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $21,601 |
| Diclofenac Sodium | 91 | $18,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $463 | $186,087150 claims |
| MerckJanuvia, Janumet Xr, Janumet | $190 | $132,254200 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Synjardy Xr, Glyxambi | $687 | $130,208181 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $1,644 | $121,614180 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Shingrix, Breo Ellipta | $957 | $98,687196 claims |
| PfizerEliquis | $48 | $37,99049 claims |
| NovartisEntresto | $123 | $36,00950 claims |
| Lilly USA, LLCMounjaro | $245 | $26,76225 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $312 | $21,60125 claims |
| BayerKerendia | $280 | $10,60915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Jersey City
- Nana SafoaahJersey City$229K
- Amer SyedJersey City$140K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.